Cancer Control最新文献

{"title":"Moderate Hypofractionated Post-Prostatectomy Radiotherapy (MYSTERY) Versus Conventionally Fractionated Post-Prostatectomy Radiotherapy (COPORT) for the Patients With Localized Prostate Cancer: The Protocol of a Prospective, Randomized Trial.","authors":"Yiyin Liang, Weiwei Zhang, Xianzhi Zhao, Huojun Zhang","doi":"10.1177/10732748251317682","DOIUrl":"10.1177/10732748251317682","url":null,"abstract":"<p><strong>Introduction: </strong>A few studies have examined whether the safety and efficacy of moderate hypofractionated post-prostatectomy radiotherapy (moderate HYPORT, also called MYSTERY) are equal to those of conventionally fractionated post-prostatectomy radiotherapy (COPORT) in patients with localized prostate cancer. Therefore, this study aims to compare the safety and efficacy of MYSTERY and COPORT in patients with postoperative prostate cancer.</p><p><strong>Methods and analysis: </strong>This study is a prospective, single-center, open-label, randomized controlled clinical trial. Patients with localized prostate cancer will be randomly allocated to receive COPORT (66-74 Gy at 2 Gy per fraction) or MYSTERY (57.5-65 Gy at 2.5 Gy per fraction). The primary outcomes are radiotherapy-related gastrointestinal and genitourinary adverse events. Secondary outcomes include progression-free survival, quality of life, medical expenses, and overall survival.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251317682"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11815805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life and Associated Factors Among Family/Caregivers of Pediatric Patients Treated for Cancer at Tikur Anbessa Specialized Hospital: Institution-Based Cross-Sectional Study.","authors":"Zenebe Negash, Eden M Kinfe, Urji Zerihun, Atalay M Fentie","doi":"10.1177/10732748251320821","DOIUrl":"10.1177/10732748251320821","url":null,"abstract":"<p><strong>Background: </strong>Pediatric cancer significantly affects the quality of life (QOL) of patients and their families/caregivers particularly in low-income countries where there is scarcity of resources. Thus, the purpose of this study was to evaluate the QOL and associated factors among family/caregivers of pediatric patients treated for cancer at Tikur Anbassa Specialized Hospital (TASH), Addis Ababa, Ethiopia.</p><p><strong>Method: </strong>An institution-based cross-sectional study design was used to collect information from family/caregivers who were present in the pediatric oncology unit at TASH from January 2, 2023 to May 30, 2023. The validated Amharic version of the caregiver oncology quality of life questionnaire (CarGOQOL) was used to collect the data. A random sampling technique was applied to select the study participants. The descriptive and regression analysis were conducted using statistical software SPSS version 27.0.</p><p><strong>Results: </strong>A total of 350 family/caregivers answered the questionnaire. The overall response rate was 82.7%, and about 55% of the respondents were women. Among the participants, under-35 age made up the majority (60.9%). About 81% of family/caregivers were parents, and 77.7% of family/caregivers were married. More than half of the participants have at least a secondary level education. In addition, about two-thirds of the participants (63%) live in rural areas. Furthermore, more than half of the participants generate less than $17.86 per month. Nearly fifty percent of family/caregivers of pediatric cancer patients had poor QOL. The finding showed that widowed family/caregivers (AOR:5.59, 95%CI: 1.12, 27.79, <i>P</i>-value: 0.03) had poor QOL as compared to married, and those with a monthly income of between $17.87- $89.29 were less likely to have poor QOL compared to those with an income below <$17.87 (<i>P</i>-value: 0.01).</p><p><strong>Conclusion: </strong>In the current study, poor QOL was high among family/caregivers of pediatric cancer patients. Being widowed and lowest income were significantly associated with the QOL of the caregivers of pediatric patients with cancer.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251320821"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11815790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Outcomes of Patients Diagnosed With Sacral Chordoma in a Retrospective Multicenter Study.","authors":"Aneta Maria Borkowska, Andrzej Pieńkowski, Paulina Chmiel, Tomasz Skóra, Radosław Michalik, Piotr Rutkowski, Mateusz Jacek Spałek","doi":"10.1177/10732748251323730","DOIUrl":"10.1177/10732748251323730","url":null,"abstract":"<p><p>BackgroundChordoma is a rare and aggressive primary bone sarcoma. En-block resection remains the primary treatment, but some patients are unable to undergo it due to the location and potential complications. Currently, there is no direct comparison of the effects of radiotherapy (RTH) and surgical treatment. However, retrospective analyses indicate the potential benefits of using RTH.MethodsA retrospective analysis was conducted on 48 patients with sacral chordoma who were treated with surgery and/or radiotherapy between 2001-2020. Among those, 22 were initially treated with surgery, 19 with definitive radiotherapy, and 7 received combined treatment. The outcomes of the treatment of recurrence in 16 patients were considered. The resection margins were defined according to R classification, and the Kaplan-Meier method was employed to calculate disease-free survival (DFS) and overall survival (OS).ResultsThe median (mOS) for the entire cohort was 80.6 months (95% CI: 62.3-NA), and the median (mDFS) was 40.4 months (95% CI: 35-69.5). Patients who underwent radical surgery of the primary tumor did not achieve the mOS (mean 68), while patients treated only with RTH for the primary tumor achieved an mOS of 62.3 months (95% CI: 52.1-NA). This resulted in a significant advantage of surgery over RTH in terms of OS (<i>P</i> = 0.01). This was not observed for DFS. The 3-year DFS rates were 65% in the surgical treatment group and 53.3% in the RTH group. The 3-year OS rates were 96% in the surgery group and 88.9% in the RTH group. In the treatment of recurrence, there were no statistically significant differences between RTH and surgery, for OS (<i>P</i> = 0.76).ConclusionsRadical surgery remains the optimal treatment for sacral chordoma. For patients who are not candidates for surgical intervention, RTH offers excellent long-term outcomes. The treatment of recurrence remains a significant challenge. Comparing modern RTH techniques and surgical procedures could provide further insights.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251323730"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143606811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological Features and Prognoses of Patients With Splenic Metastases From Breast Cancer: A Single-Centre, Retrospective Study.","authors":"Xiaofeng Xie, Mingrui Ma, Xue Bai, Jing Hu, Haijie Zheng, Xiongqi Guo, Jiayi Huang, Xuelian Chen, Liping Chen, Xiaofeng Lan, Lin Song, Caiwen Du","doi":"10.1177/10732748241310578","DOIUrl":"10.1177/10732748241310578","url":null,"abstract":"<p><strong>Purpose: </strong>Splenic metastases (SM) from breast cancer (SMBC) are exceedingly rare. To date, the relevant literature is primarily based on pan-tumour species, with only a few studies exploring SM specifically in relation to breast cancer. As such, the present retrospective study explored the clinicopathological characteristics and prognoses of patients with SMBC at the breast care centre of the authors' hospital.</p><p><strong>Methods: </strong>Data from patients newly diagnosed with metastatic breast cancer (MBC) between June 2017 and June 2022 were extracted from medical records at the authors' hospital. Clinicopathological characteristics and their associations with progression-free survival (PFS [time from diagnosis of initial recurrence and/or metastasis to diagnosis of SM]), first overall survival (^1stOS [time from diagnosis of breast cancer to death or last follow-up visit]), and second overall survival (^2ndOS [time from diagnosis of SM to death or last follow-up visit]) were analysed in patients with SMBC.</p><p><strong>Results: </strong>In total, 1009 patients with MBC were identified, of whom 18 (1.7%) had SM. T1 and T2 stages were documented in 15 (83.3%) patients, whereas N2 and N3 were documented in 13 (62.2%). 14 (77.8%) patients were oestrogen receptor and/or progesterone receptor positive. A Ki-67 index ≥ 30% accounted for 72.2% (13/18) of cases, and all patients were histological grade II or III. Liver and/or lung metastases were documented in all 18 (100%) patients. Median PFS was 6.3 months. The median ^1stOS and ^2ndOS were 41.8 and 10.6 months, respectively. The number of previous treatment lines before diagnosis of SM was a significant adverse prognostic factor for PFS, and disease-free survival was a significant adverse prognostic factor for ^1stOS.</p><p><strong>Conclusion: </strong>SMBC commonly presents with diffuse multiple organ metastases in the terminal stage of malignancy and has a poor prognosis, which may provide deeper insight into SMBC for clinicians.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241310578"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge of Human Papillomavirus, Risk Factors and Screening for Cervical Cancer Among Women in Ghana.","authors":"Yvonne Nartey, Kwabena Amo-Antwi, Betty Osei-Ntiamoah, Philip C Hill, Edward T Dassah, Richard H Asmah, Kofi M Nyarko, Ramatu Agambire, Thomas O Konney, Joel Yarney, Nelson Damale, Brian Cox","doi":"10.1177/10732748251323765","DOIUrl":"10.1177/10732748251323765","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer ranks as the fourth most common cancer among women, with 662,301 new cases and 348,874 deaths reported in 2022. The majority of the disease burden occurs in low- and middle-income countries. In Ghana, there were 3072 new cases and 1815 deaths reported in 2022. While human papillomavirus (HPV) infection, a key cause for cervical cancer, resolves in most individuals, it can progress to cancer in some. This has led to research into other factors that may, in conjunction with HPV, increase the risk of cervical cancer progression. Improving knowledge of HPV, risk factors, and screening will be important in reducing the burden of cervical cancer. In this study, we investigate the knowledge on HPV, risk factors, and cervical screening among women in Ghana.</p><p><strong>Methods: </strong>A hospital-based case-control study was conducted among women aged 18 to 95 years. This involved Ghanaian women diagnosed with cervical cancer and hospital controls. Data were collected using a structured questionnaire, and basic descriptive analyses were performed.</p><p><strong>Results: </strong>Results from the 206 cases and 230 controls revealed limited knowledge about HPV and its role in cervical cancer development, with minimal disparity between women with (2.4%) and without (6.5%) cervical cancer. The majority of participants lacked awareness of HPV transmission (95.9%), and awareness of HPV vaccination was low (3.5%). Barriers to HPV vaccination included insufficient awareness about HPV, limited access to vaccination centers, and cost concerns. Respondents expressed a preference for educational programs delivered through church, radio, and television channels.</p><p><strong>Conclusions: </strong>Knowledge of HPV, risk factors, and cervical screening was found to be very low among Ghanaian women. These findings underscore the need for a comprehensive cervical cancer educational initiative within Ghana's national cervical cancer control policy to mitigate the disease's impact.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251323765"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Influencing Immunotherapy Outcomes in Cancer: Sarcopenia and Systemic Inflammation.","authors":"Enes Ucgul","doi":"10.1177/10732748251318393","DOIUrl":"10.1177/10732748251318393","url":null,"abstract":"","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251318393"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National Cancer Registries in Bangladesh and Social Determinants of Health: Challenging Cancer Disparities.","authors":"Jabed Iqbal","doi":"10.1177/10732748251323757","DOIUrl":"10.1177/10732748251323757","url":null,"abstract":"","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251323757"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143525028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response: From Diagnosis to Survivorship: How the Tumor Board Establishment Facilitation Forum (TEFF) Shapes the Breast Cancer Journey in Pakistan.","authors":"Fatima Shaukat, Kanza Farhan, Nayab Shahid, Zainab Anwar, Marrium Sultan Dar","doi":"10.1177/10732748251331746","DOIUrl":"10.1177/10732748251331746","url":null,"abstract":"","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251331746"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143732581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychotherapeutic Applications of the SASB Cluster Analysis of Intrapsychic Behaviors in Women With Breast Cancer: A Step by Step Approach.","authors":"Anna Vespa, Roberta Spatuzzi, Paolo Fabbietti, Maria Velia Giulietti","doi":"10.1177/10732748241302868","DOIUrl":"10.1177/10732748241302868","url":null,"abstract":"<p><p>BackgroundThis study describes the approach and phases of psychotherapeutic interventions in women with breast cancer on the basis of a personality cluster analysis performed using the Structural Analysis of Social Behavior (SASB) Model by Lorna S. Benjamin.MethodsThe SASB Model is a tool for diagnosing and planning the stages of psychotherapeutic intervention. Therefore, based on the cluster analysis of the intrapsychic problems of the 2 different profiles SASB-Love and Autonomy and SASB-Control and Hate Traits, it was possible to describe the phases and methods of the psychotherapeutic SASB intervention for each profile and the most suitable therapeutic approaches.ResultsThe results of the analysis, based on the intrapsychic profile derived from the SASB model and distributed along a continuum, indicate the need for specific psychotherapeutic interventions. Although some common intrapsychic issues were identified, their intensity varied across individuals, suggesting that tailored therapeutic approaches are necessary for each patient. The identified intrapsychic profiles, characterized by passive adaptation, low self-affirmation, and self-criticism, highlight the importance of facilitating self-contact, enhancing self-awareness, and promoting the elaboration and integration of emotional experiences.ConclusionIn this context, a targeted psychotherapeutic treatment aimed at fostering self-affirmation and reducing self-criticism can help women with breast cancer to transform their approach to dealing with their condition, leading to more effective adaptation and improved quality of life.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241302868"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Body Mass Index (BMI) on Clinical Outcomes for Patients Receiving Systemic Anti-Cancer Therapies for Advanced Clear Cell Renal Carcinoma.","authors":"John Greene, Zhe Wang, Benjamin H L Harris, David Dodwell, Simon R Lord","doi":"10.1177/10732748251317681","DOIUrl":"10.1177/10732748251317681","url":null,"abstract":"<p><p>IntroductionObesity is a risk factor for the development of renal cell carcinoma (RCC), however observational studies have suggested patients with RCC receiving systemic anti-cancer therapy (SACT) and BMI ≥25 kg/m² may have a better prognosis than patients with a normal or low BMI, a phenomenon often referred to as the obesity paradox.MethodsThe impact of BMI on survival outcomes in patients with advanced clear cell RCC receiving SACT within the National Health Service (NHS) in England between 2010 and 2018 was investigated. A retrospective analysis was performed using the SACT dataset from NHS-England.ResultsA total of 1034 patients were included. The majority of patients commenced treatment with oral SACT, pazopanib (53.3%) and sunitinib (43.7%). Median overall survival for patients with BMI ≤25 kg/m² was 12.6 months (95% CI; 10.1-14.4) and 17.9 months (15.4-20.0) for patients with BMI ≥25 kg/m² (<i>P</i> < .001). The association between BMI and improved survival was greatest in the first year of commencing SACT with the adjusted mortality rate of 68.9% for patients with BMI less than 25 kg/m² compared to 48.6% for patients with BMI greater than 25 kg/m² (rate ratio .77, .63 to .93).ConclusionA high BMI compared to a normal or low BMI was associated with improved survival in patients with metastatic RCC who were predominantly treated with oral SACT. Improved survival in obese patients with advanced RCC may be associated with improved response to systemic targeted therapies.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251317681"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915284/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}